Strains of gonococcus were shown to be immunologically heterologous. Serum bactericidal activity generally correlated with induced immunity to gonococcal challenge as detected by the guinea pig subcutaneous chamber model. Sera devoid of bactericidal activity reflected the lack of cross-protection in subcutaneous chambers. Factors affecting the bactericidal assay described in this report include (i) source of complement, (ii) concentration of test antigen and complement activity, and (iii) presence of calcium and magnesium ions and bovine serum albumin in diluent. Poor correlation was observed between agglutinating activity of the immune sera and protection.
Strains of gonococcus were shown to be immunologically heterologous. Serum bactericidal activity generally correlated with induced immunity to gonococcal challenge as detected by the guinea pig subcutaneous chamber model. Sera devoid of bactericidal activity reflected the lack of cross-protection in subcutaneous chambers. Factors affecting the bactericidal assay described in this report include (i) source of complement, (ii) concentration of test antigen and complement activity, and (iii) presence of calcium and magnesium ions and bovine serum albumin in diluent. Poor correlation was observed between agglutinating activity of the immune sera and protection.
Knowledge of immunological properties of gonococcal strains is essential both for the understanding of gonococcal immunity and for the development of vaccines. Immunological diversity of nine strains of Neisseria gonorrhoeae was demonstrated by cross-protection in guinea pig subcutaneous chambers (4) . Since the procedure described for immunotyping is elaborate and is not suitable for large-scale screening or typing of clinical isolates, attempts were made to correlate the results of immunotyping with those obtained by experimental serotyping procedures. Our results are presented in this report.
MATERIALS AND METHODS
Bacterial cultures. The nine strains of Neisseria gonorrhoeae used in this study were described previously (4) .
Gonococcal immune sera. Antisera for each of the nine gonococcal strains were prepared in Hartley strain guinea pigs weighing approximately 300 g each. The guinea pigs were injected weekly for 11 weeks by the subcutaneous route with type 1 (Ti) living cultures containing 109 colony-forming units (CFU). Blood was obtained by cardiac puncture with a 25-gauge needle from animals under light anesthesia.
Bactericidal antibody assay. The appropriate gonococcal strains were grown on GC base (GCB) medium supplemented with IsoVitaleX (Baltimore Biological Laboratories, Baltimore, Md.) overnight at 37°C in a candle jar. Bacterial growth was suspended in glass tubes (13 by 100 mm) containing Trypticase soy broth (TSB) (30 g/liter of distilled water). The suspension was adjusted to an optical density of 0.5 units with a Leitz spectrophotometer at 535 nm and was then diluted 1:100 in TSB for use in the bactericidal assay. The diluted suspension contained approximately 10" CFU per ml.
The diluent used throughout the assay was phosphate-buffered saline (PBS), pH 7.2, containing 0.006% MgCl2 6H20, 0.004% CaCl2 2H20, and 1% bovine serum albumin. Guinea pig complement (Texas Biologicals, Fort Worth, Tex., lot 507) or fresh chimpanzee serum was used. Complement preparations were pretested to determine that the bacteria used were not nonspecifically killed in the complement. Complement was stored at -70°C until used.
All sera to be tested, including reactive and nonreactive controls, were heated for 30 min at 56°C. Serial twofold dilutions were made by using microtiter loops to transfer 0.025 ml of each serum and the controls to microtiter U-bottom plates (Ames, Elkhart, Ind.) containing 0.025 ml of 1:10 dilution of complement. As a serum control, 0.025 ml of the diluent (without complement) was added to 0.025 ml of each heated serum. For complement control, serial twofold dilutions of the complement were made in diluent by using 0.025-ml microtiter loops.
A 0.025-ml portion of the appropriate antigen suspension was added to each serum dilution and the controls, and the mixtures were incubated at room temperature for 90 min.
A micropipetting gun (Clay Adams, Parippany, N.J.) was used to deliver 10 gl of the reaction mixture to plates containing GCB with IsoVitaleX and vancomycin, colistin, and nystatin (7 
RESULTS
Bactericidal activity of immune guinea pig sera. Serum bactericidal titers generally correlated with increased resistance to gonococcal challenge as determined in a previous paper (4) by using the guinea pig subcutaneous chamber model ( Table 1 ). Titers of 32 or above were generally associated with protection; minor exceptions were observed with strains b, f, and h. Strain d reacted with all the nine immune sera, but protection was observed primarily with the homologous organism and, to a much less extent, with challenge strains e and f. Protection in subcutaneous chambers was negligible when the cross-reacting bactericidal titer was 8 The effect of complement from two animal species on bactericidal activity is summarized in Table 2 . Guinea pig complement generally yielded higher strain-specific titers than chimpanzee complement. Table 3 indicates that the source of complement affected the specificity of the immune sera. More low-grade cross-reactions were observed with chimpanzee comple- Agglutinating activity of immune sera in relation to protection. Agglutinating activity of the immune sera did not correlate well with protection (Table 5 ). Strain a agglutinated in a, c, and i immune sera, but protection was observed only with the homologous strain a challenge. Strain b did not agglutinate in a, c, and h antisera, but there was significant cross-protection in guinea pigs immunized with these heterologous strains. Strain c agglutinated in e, h, and i antisera with no detectable crossprotection. Guinea pigs immunized with strains, a, c, e, or h were protected against challenge with strain f with no observable agglutinating activity of strain f in the respective heterologous antisera. Although strain i agglutinated to the same extent in a and c antisera, animals immunized with c were highly protected against i challenge, but had no detectable immunity to strain a. Agglutinating activity of antisera was not indicative of cross-protection.
Poor correlation was observed between agglutinating and bactericidal activities of the immune sera (Table 6 ). When strain a was used as antigen, a and c antisera were shown to have an agglutinating titer of 256, but bactericidal activity of the a antiserum was eight times higher than that of the c antiserum. Antiserum against i agglutinated strain a at a titer of 64 with no demonstrable bactericidal activity. Antisera a and h had high bactericidal activity against strain b although agglutinating activity was absent. Antiserum a was highly bactericidal to strains f and h with no agglutinating 
Titers are expressed as the end-point dilution factor of the serum dilution. b Protection is graded according to the base 10 logarithm of the median infecting dose in CFU of gonococci as determined in a previous study by using the guinea subcutaneous chamber model: 0 to 2.5, negative; 2.6 to 3.5, 1+; 3.6 to 4.5, 2+; 4.6 to 5.5, 3+; >5.6, 4+. (1) . Distinct immunotypes were established, and the potential usefulness of immunotyping for epidemiological work and for understanding of gonococcal immunity was discussed.
In the present study, a close correlation between immunotypes and bactericidal activity of immune sera was demonstrated. The profile of cross-protection generally paralleled bactericidal activity of the immune sera. Discrepancies were observed with three strains at low cross-reacting titers between 4 and 16, which may be attributed to the difference in sensitivity of the in vivo immunotyping and the in vitro bactericidal systems, and to the fact that some gonococcal strains were more susceptible to complement-dependent bactericidal activity than others. Immune sera with bactericidal titers of 32 The effects of complement preparations from two different animal species on specificity and titer of the immune sera were interesting. Larger numbers of low grade cross-reactions were observed with chimpanzee complement than with guinea pig complement. In addition, guinea pig complement generally yielded higher bactericidal activity of the immune sera than did chimpanzee complement.
Agglutinating activity did not correlate with protection, nor did it parallel bactericidal activity. The presence of pili on the cells probably was largely responsible for the agglutinating activity, since sera from guinea pigs immunized with Ti cells did not agglutinate T3 cells of the same strain (2) . The inability of pili to confer immunity in guinea pigs has been reported by Turner and Novotny (9) . The protective role of pili in chimpanzees has not yet been conclusively demonstrated.
With sera from chimpanzees immunized with Ti bacterin, Arko and associates (3) reported that serum bactericidal tests correlated most closely with the resistance of individual chimpanzees challenged in the pharynx and urethra with graduated doses of gonococci 1 month after the last immunization. These findings are consistent with our results obtained with the guinea pig subcutaneous chamber model, and they provide further evidence that bactericidal antibody is probably significant in induced immunity of animals to gonococcal infection.
The immunotyping system previously described (4) yielded valuable epidemiological and immunological information on gonococcal strains. Undoubtedly, more immunotypes will be established as the work continues, but this system is too elaborate for use in the mass screening of clinical isolates. We are using the bactericidal system described in this report for preliminary grouping of isolates from a defined clinical population. Confirmation of a new immunotype is performed in animals.
